The nephroprotective potential of SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin has been impressively demonstrated in several clinical trials in patients with type II diabetes (Zinman et al., 2015; Wanner et al., 2016; Neal et al., 2017; Wiviott et al., 2019). Here, SLC5A2 is linked to type 2 diabetes mellitus.